https://qilindo.com/wp-content/uploads/2021/08/Approved-Pulsewave-explainer-video-1.mp4
Pulsewave AG
Health Monitoring
Play Video
Play Video
Video
Presentation
One Pager
Favorites
Raising
$1,500,000
in exchange for
15%
Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email
Industry
Medical
Company Size
2-5
Patent
Pending
Location
Israel
Languages
English, Hebrew
Website URL
Overview
The Team
Problem & Solution
The Market
A discreet monitoring device fixed on any eyeglasses frame that collects vital information, processes it via deep learning algorithms, and makes it available for doctors before CVD events can occur.
- All day
- Real-time
- Long term
- AI supported
- Pre/Post event
Either slide & clip on, or have an Optician replace the temple ends with TempleGuard.
The Vision
Make vital information available to doctors before CVD events occur.
The Product
“TempleGuard” is a wearable device that attaches to eyeglasses and measures vital signs from behind the ear. The device combines real-time patient monitoring with AI algorithms in order to predict the development of CVD (Cardio-Vascular Disease).
Two extensive rounds of IP research with the Swiss Federal Institute of Intellectual Property showed no existing relative patents.
We filed a full US Patent Application (No. 17/109,934) on Dec. 2nd, 2020.
Overview
A discreet monitoring device fixed on any eyeglasses frame that collects vital information, processes it via deep learning algorithms, and makes it available for doctors before CVD events can occur.
- All day
- Real-time
- Long term
- AI supported
- Pre/Post event
Either slide & clip on, or have an Optician replace the temple ends with TempleGuard.
The Vision
Make vital information available to doctors before CVD events occur.
The Product
“TempleGuard” is a wearable device that attaches to eyeglasses and measures vital signs from behind the ear. The device combines real-time patient monitoring with AI algorithms in order to predict the development of CVD (Cardio-Vascular Disease).
Two extensive rounds of IP research with the Swiss Federal Institute of Intellectual Property showed no existing relative patents.
We filed a full US Patent Application (No. 17/109,934) on Dec. 2nd, 2020.
Problem & Solution
17.9 million people died from CVD in 2018, representing 31% of all global deaths.
30% of CVD monitoring devices are abandoned within 6–12 months, mainly due to inconvenience.
Our product ‘TempleGuard’ will solve the problem of a convenient & discreet vital sign monitor, which is small and capable enough to collect cardiac indicators that are associated with blood pressure and arterial stiffness in real-time, throughout the day and over the course of years.
Please Sign In or Register to view this content.